Company
Biogen
Biogen has 43 drugs tracked on RxWires: 7 post-market, 1 approved, 14 in Phase 3, 6 in Phase 2, 3 in Phase 1/2, 12 in Phase 1.
- Ticker
- BIIB
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Dosing Interruption of Natalizumab | Post-Market | Multiple Sclerosis |
| Nusinersen | Post-Market | Muscular Atrophy, Spinal |
| Interferon-beta-1a | Post-Market | Relapsing-Remitting Multiple Sclerosis |
| Interferon-beta-1a (Avonex) plus methylprednisolone | Post-Market | Relapsing-remitting Multiple Sclerosis |
| TYSABRI and AVONEX | Post-Market | Relapsing-remitting Multiple Sclerosis |
| dimethyl fumarate | Post-Market | Multiple Sclerosis |
| peginterferon beta-1a | Post-Market | Relapsing Remitting Multiple Sclerosis |
| TYSABRI | Approved | |
| Aducanumab | Phase 3 | Alzheimer's Disease |
| SAGE-217 | Phase 3 | Major Depressive Disorder |
| Tofersen | Phase 3 | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation |
| Felzartamab | Phase 3 | Antibody-mediated Rejection |
| Salanersen | Phase 3 | Muscular Atrophy, Spinal |
| Omaveloxolone | Phase 3 | Friedreich Ataxia |
| BIIB017 (peginterferon beta-1a) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting |
| BG00012 (dimethyl fumarate) | Phase 3 | Healthy |
| Litifilimab | Phase 3 | Systemic Lupus Erythematosus (SLE) |
| lixivaptan | Phase 3 | Hyponatremia With Normal Extracellular Fluid Volume |
| Bardoxolone methyl | Phase 3 | Pulmonary Hypertension |
| ALKS 8700 | Phase 3 | Relapsing Remitting Multiple Sclerosis |
| Simvastatin | Phase 3 | Relapsing Remitting Multiple Sclerosis |
| BIIB122 | Phase 3 | Parkinson Disease |
| RTA 402 Dose1 | Phase 2 | Malignant Melanoma |
| BIIB033 (anti-LINGO-1 mAb) | Phase 2 | Acute Optic Neuritis |
| PF-04958242 | Phase 2 | Cognitive Impairment Associated With Schizophrenia (CIAS) |
| CNV1014802 | Phase 2 | Trigeminal Neuralgia |
| BIIB021 | Phase 2 | Breast Cancer |
| Alefacept | Phase 2 | Psoriasis |
| rituximab | Phase 1/2 | Lymphoma |
| BIIB147 | Phase 1/2 | Amyotrophic Lateral Sclerosis |
| Zevalin Radioimmunotherapy | Phase 1/2 | Lymphoma |
| [14C]-Omaveloxolone | Phase 1 | Healthy Male Subjects |
| BG00010 IV | Phase 1 | Painful Lumbar Radiculopathy |
| GSK1014802 low dose | Phase 1 | Pain, Neuropathic |
| BIIB115 | Phase 1 | Healthy Volunteer |
| BIIB132 | Phase 1 | Spinocerebellar Ataxia Type 3 |
| BIIB076 | Phase 1 | Alzheimer's Disease |
| Galiximab | Phase 1 | Lymphoma, Non-Hodgkin's |
| BIIB118 | Phase 1 | Healthy Adult Subjects |
| RTA 744 | Phase 1 | Glioma |
| BIIB091 | Phase 1 | Healthy Volunteers |
| BIIB074 | Phase 1 | Neuropathic Pain |
| [14C] BIIB122 ([14C] DNL151) | Phase 1 | Healthy Volunteers |
Latest
- biogen filed 8-K
- biogen filed 8-K
- Licensing / Collaboration Deal: biogen
- biogen filed 8-K
- Merger or Acquisition: biogen
Follow Biogen on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.